Larry Schaaf J. PhD

Larry Schaaf J. PhD
DirectorOffice of Health Sciencesschaaf.34@osu.edu
1232B James Cancer Hosp & Res Inst 300 W 10th Avenue Columbus Ohio 43210
Phone:614-293-6851Fax: (614) 293-4072
  • Non-Member

General Research Interest

Clinical Pharmacy

Research Description

Larry J. Schaaf, PhD is Director of the Clinical Treatment Unit (CTU) at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. Dr. Schaaf has extensive experience in pharmacokinetics and early clinical trials and has played a key role in the development and clinical application of a number of widely used anti-cancer drugs, including irinotecan, exemestane, and epirubicin. Dr. Schaaf also manages the Clinical Trials Processing Laboratory (CTPL) which is responsible of procurement, processing, storage and shipment of the majority of correlative science specimens collected as part of phase I trials.

Transinstitutional Work

Dr. Schaaf collaborates with a number of investigators in designing the pharmacokinetic and pharmacodynamic components of clinical trials. As Director of the Clinical Trials Processing Laboratory, he insures that correlative research specimens collected at OSU but analyzed at outside institutions are properly processed, stored and shipped

Current Publications

  • Phelps MA, Stinchcombe TE, Blachly JS, Zhao W, Schaaf LJ, Starrett SL, Wei L, Poi M, Wang D, Papp A, Aimiuwu J, Gao Y, Li J, Otterson GA, Hicks WJ, Socinski MA, Villalona-Calero MAErlotinib in african americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.Clin Pharmacol Ther 96 182-91 8/1/2014
  • Walker AR, Klisovic RB, Garzon R, Schaaf LJ, Humphries K, Devine SM, Byrd JC, Grever MR, Marcucci G, Blum WPhase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.Leuk Lymphoma 55 1304-8 6/1/2014
  • Patnaik A, Papadopoulos KP, Tolcher AW, Beeram M, Urien S, Schaaf LJ, Tahiri S, Bekaii-Saab T, Lokiec FM, Rezaï K, Buchbinder APhase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.Cancer Chemother Pharmacol 71 1499-506 6/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu